Skip to main content

Update on CSL COVID-19 Vaccine Manufacturing Numbers

news

Melbourne, Australia: CSL can confirm that production of the AstraZeneca COVID-19 vaccine for Australia has reached more than a million doses a week - these volumes have been produced for a number of weeks and are due to be released into the community from mid-late May following required quality checks.

To date, more than 3.7 million COVID-19 vaccines have been released from CSL and Seqirus’ Australian manufacturing facilities. 

To ensure that the vaccines meet the required quality standards there is approximately a four week quality control and approval process from the time vials are filled, involving a series of stringent tests conducted on each batch and undertaken by CSL, AstraZeneca and the TGA.

Manufacturing any biological product at industrial scale involves a high degree of fine-tuning to achieve optimal levels of production. The teams at CSL Behring and Seqirus have been working to improve processes and increase output, and we are pleased to now be delivering targeted volumes. 

There are a number of inherent variables in production of biological products and because of this the number of doses from each batch will continue to vary - this is normal and expected.  

CSL is proud of its ongoing role to support Australia’s vaccination efforts and the team continues to work around the clock to produce safe and effective vaccines for the country.

 

- ENDS -

About CSL

CSL (ASX:CSL; USOTC:CSLLY) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our two businesses, CSL Behring and Seqirus – provides life-saving products to more than 70 countries and employs more than 27,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit Vita at CSLBehring.com/Vita and follow us on Twitter.com/CSL

For more information about CSL Limited, visit www.csl.com.au